The impact of direct-to-consumer marketing of cancer genetic testing on women according to their genetic risk

Genetics in Medicine

Volumn 10, Issue 12, 2008, Pages 888-894

  Lowery, Jan T ^a,d   Byers, Tim ^a   Axell, Lisen ^b   Ku, Lisa ^b   Jacobellis, Julian ^c  

^a Global Health and Health Disparities   (United States)

^b UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^c Colorado Department of Public Health and Environment ^*  (United States)

^d UNIVERSITY OF COLORADO   (United States)

Author keywords

BRACAnalysis; BRCA1; BRCA2; Direct to consumer marketing; Genetic testing

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ADULT; ANAMNESIS; ARTICLE; BREAST CANCER; CANCER GENETICS; CANCER RISK; DIAGNOSTIC ACCURACY; FAMILY HISTORY; FEMALE; GENE MUTATION; GENETIC RISK; GENETIC SCREENING; HEALTH SURVEY; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MEDICAL INFORMATICS; ONCOGENE; OVARY CANCER; TELEPHONE;

ADULT; BRCA1 PROTEIN; BREAST NEOPLASMS; COLORADO; CONSUMER HEALTH INFORMATION; FEMALE; GENETIC COUNSELING; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HEALTH PROMOTION; HUMANS; MARKETING OF HEALTH SERVICES; MIDDLE AGED; MUTATION; OVARIAN NEOPLASMS; RISK; WOMEN;

EID: 58149233903     PISSN: 10983600     EISSN: None     Source Type: Journal    
DOI: 10.1097/GIM.0b013e31818de6d7     Document Type: Article

References (20)

1. Myriad Genetics Laboratories, Inc., 2002. Myriad genetics launches direct to consumer advertising campaign for breast cancer test Available at: http://www.myriad.com/news/release/333030. Accessed April 30, 2008.
2. Newman B, Mu H, Butler CM, Millikan RC, Moorman PG, King MC. Frequency of breast cancer attributable to BRCAl in a population-based series of American women. JAMA 1998;279:915-921.
3. Peto J, Collins N, Barfoot R, et al. Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst 1999;91:943-949.
4. Syrjakoski K, Vahteristo P, Eerola H, et al. Population-based study of BRCA1 and BRCA2 mutations in 1035 unselected Finnish breast cancer patients. J Natl Cancer Inst 2000;92:1529-1531.
5. Easton DF, Ford D, Bishop DT, the Breast Cancer Linkage Consortium. Breast and ovarian cancer incidence in BRCA1 mutation carriers. Am J Hum Genet 1995;56:265-271.
6. Cancer Facts and Figures, 2006. Atlanta, GA: American Cancer Society. Available at: http://www.cancer.org. Accessed January 31, 2008.
7. Centers for Disease Control and Prevention (CDC). Genetic testing for breast and ovarian cancer susceptibility: evaluating direct-to-consumer marketing - Atlanta, Denver, Raleigh-Durham, and Seattle, 2003. MMWR Morb Mortal Wkly Rep 2004;53:603-606.
8. Parmigiani G, Berry DA, Aguilar O. Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet 1998;62:145-158.
9. Nelson N. Cancer Genetics Network gets under way with 5 years of funding. J Natl Cancer Inst 1997;89:10-11.
10. Senior K. New US carcer genetics network announced. Mol Med Today 1998;4:459-460.
11. Myriad, 2003. Mutation prevalence tables. Available at: http://www.myriad-tests.com/provider/mutprevo.htm. Accessed May 30, 2003.
12. National Comprehensive Cancer Network (NCCN), 2008. Available at http://www.nccn.org/. Accessed August 29, 2008.
13. Mouchawar J, Hensley-Alford S, Laurion S, et al. Impact of direct-to-consumer advertising for hereditary breast cancer testing on genetic services at a managed care organization: a naturally-occurring experiment Genet Med 2005;7:191-197.
14. Hartman LC, Schaid D, Sellers T, et al. Bilateral prophylactic mastectomy in BRCA1/2 mutation carriers. Proc Am Assoc Cancer Res 2001;41:222-223.
15. Rebbeck TR, Lynch HT, Neuhausen SL, Narod SA, et al. Prophylactic oophorectomy in carriers of BRCA1 and BRCA2 mutations. N Engl J Med 2002;346:1616-1622.
16. Gollust SE, Chandras Hull S, Wilfond BS. Limitations of direct-to-consumer advertising for clinical genetic testing. JAMA 2003;289:45-46.
17. Mouchawar J, Laurion S, Ritzwoller DP, Ellis J, et al. Assessing controversial direct-to-consumer advertising for hereditary breast cancer testing: reactions from women and their physicians in a managed care organization. Am J Manag Care 205;11:601-608.
18. Claus EB, Schildkraut JM, Thompson WD, Risch NJ. The genetic attributable risk of breast and ovarian cancer. Cancer 1996;77:2318-2324.
19. Easton DR, Pooley KA, Dunning AM, Pharoah PD, et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 2007;447:1087-1095.
20. Myriad Genetics Laboratories, Inc., 2007. Myriad genetics launches awareness advertising campaign to educate women about hereditary risks of breast and ovarian cancers. Available at: http://www.myriad.com/news/release/1049527. Accessed May 30, 2008.